I have never seen a reverse split result in better financing.
OWCP is a empty shell without assets or revenue - the only option is toxic financing.
If their patent applications had any value there would be financiers Lining up to provide capital - just as they did for GWP - but the pharmaceutical investors understand the OWCP patent applications are worthless.
IG
"Are you gonna pull those pistols or whistle Dixie?"